CN Patent

CN113527213B — 促性激素释放激素受体拮抗剂及其用途

Assigned to Shijiazhuang Yiling Pharmaceutical Co Ltd · Expires 2023-01-03 · 3y expired

What this patent protects

促性激素释放激素受体拮抗剂及其用途。本发明涉及有机化学领域，特别是涉及一种化合物或其药学上可接受的盐、异构体、前药、多晶型物或溶剂化物及其制备方法和用途。本发明提供一种化合物或其药学上可接受的盐、异构体、前药、多晶型物或溶剂化物，所述化合物的化学结构式如式I所示。本发明提供的化合物在钙流检测实验中作为GnRHR拮抗剂，活性与Elagolix相当或更优，且具有更好的药代动力学特性。

USPTO Abstract

促性激素释放激素受体拮抗剂及其用途。本发明涉及有机化学领域，特别是涉及一种化合物或其药学上可接受的盐、异构体、前药、多晶型物或溶剂化物及其制备方法和用途。本发明提供一种化合物或其药学上可接受的盐、异构体、前药、多晶型物或溶剂化物，所述化合物的化学结构式如式I所示。本发明提供的化合物在钙流检测实验中作为GnRHR拮抗剂，活性与Elagolix相当或更优，且具有更好的药代动力学特性。

Drugs covered by this patent

Patent Metadata

Patent number: CN113527213B
Jurisdiction: CN
Classification: —
Expires: 2023-01-03
Drug substance claim: No
Drug product claim: No
Assignee: Shijiazhuang Yiling Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.